2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome

✍ Scribed by Elias Jabbour; Srdan Verstovsek; Francis Giles; Varsha Gandhi; Jorge Cortes; Susan O'Brien; William Plunkett; Guillermo Garcia-Manero; C. Ellen Jackson; Hagop Kantarjian; Michael Andreeff

• Publisher: John Wiley and Sons
• Year: 2005
• Tongue: English
• Weight: 81 KB
• Volume: 104
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/cncr.21186

✦ Synopsis

Abstract

BACKGROUND

Hypereosinophilic syndrome (HES) is a rare, disabling, and incurable disease. In this study, a combination of 2‐chlorodeoxyadenosine (2‐CdA) and cytosine arabinoside (ara‐C) chemotherapy was evaluated in patients with HES.

METHODS

Nine patients with HES were treated with ara‐C (1 g/m^2^) given intravenously over 2 hours at 0 hours, 48 hours, 72 hours, 96 hours, and 120 hours; and 2‐CdA (12 mg/m^2^ per day) was given as a continuous intravenous infusion over 5 days starting at 24 hours. A second course of the same therapy was administered in patients who had a response.

RESULTS

All patients had signs and symptoms of end‐organ involvement. The median time from diagnosis to therapy was 25 months. Seven patients had received prior therapies. Five patients (55%) achieved a complete remission (CR), 1 after receiving 2 courses of therapy. Elimination of eosinophilia was accompanied by the resolution of symptoms. The median disease‐free survival and overall survival after the diagnosis for patients who achieved CR was 26 months and 44 months, respectively. Treatment was tolerated well. Febrile neutropenia occurred in 28% of the 14 courses that were given. The median time to recovery from neutropenia and thrombocytopenia was 17 days and 39 days, respectively.

CONCLUSIONS

The combined 2‐CdA and ara‐C chemotherapy regimen had activity in patients with HES. Cancer 2005. © 2005 American Cancer Society.